V-Nano aims to become the European leader as contract development and manufacturing organization (CDMO) for precision therapies. V-Nano manages the complete development of a wide range of active pharmaceutical ingredients (API):

• Cytotoxic or high potency API
• Conventional API
• Large molecules
• Small molecules

to be vectorized in a sterile process for parenteral formulations. The core of V-Nano business revolves around complete manufacturing and formulation approaches for specialty and orphan drug pharmaceutical companies through an entirely new model leveraging, among other things: 

• State-of-the-art dedicated nanotechnology platform
• Cutting edge fill and finish line
• Dedicated pilot-scale laboratory for scale-up
• High performing and experienced formulation and characterization department